Proactive Investors - Run By Investors For Investors

Healthcheck on cell therapy group MaxCyte

MaxCyte Inc (LON:MXCT) updates investors on its cellular editing technology ahead of new results out tomorrow.
CEO Doug Doefler tells Proactive London why short/medium and long term goals for the company are bang on track as he looks forward to a  new generation of cell therapy techniques that MaxCyte intends to develop.
The company provides patented, high-performance cell-engineering platforms to bio-pharmaceutical partners engaged in drug discovery and development, bio-manufacturing and cell therapy, including gene editing and immuno-oncology.

 
Meet Legend Mining Ltd and Cardinal Resources at our event, Melbourne , 16 July 2019. Register here »
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use